Tickertape - Financial freedom begins here

Net Loss of Jayshree Chemicals reported to Rs 0.16 crore in the quarter ended March 2025 as against net loss of Rs 3.46 crore during the previous quarter ended March 2024. Sales rose 24.19% to Rs 4.21 crore in the quarter ended March 2025 as against Rs 3.39 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 0.27 crore in the year ended March 2025 as against net loss of Rs 3.51 crore during the previous year ended March 2024. Sales rose 31.75% to Rs 16.89 crore in the year ended March 2025 as against Rs 12.82 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales4.213.39 24 16.8912.82 32 OPM %-4.51-76.11 --3.49-23.48 - PBDT0-2.38 100 0.21-1.97 LP PBT-0.08-2.44 97 -0.05-2.22 98 NP-0.16-3.46 95 -0.27-3.51 92 Powered by Capital Market - Live

Net profit of SBI Life Insurance Company rose 0.33% to Rs 813.51 crore in the quarter ended March 2025 as against Rs 810.80 crore during the previous quarter ended March 2024. Sales declined 5.00% to Rs 23860.71 crore in the quarter ended March 2025 as against Rs 25116.47 crore during the previous quarter ended March 2024. For the full year,net profit rose 27.43% to Rs 2413.30 crore in the year ended March 2025 as against Rs 1893.78 crore during the previous year ended March 2024. Sales rose 4.31% to Rs 84059.83 crore in the year ended March 2025 as against Rs 80587.10 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales23860.7125116.47 -5 84059.8380587.10 4 OPM %-1.88-3.14 -1.600.50 - PBDT900.63851.13 6 2692.602077.79 30 PBT900.63851.13 6 2692.602077.79 30 NP813.51810.80 0 2413.301893.78 27 Powered by Capital Market - Live

Net Loss of BDR Buildcon reported to Rs 0.04 crore in the quarter ended March 2025 as against net loss of Rs 0.03 crore during the previous quarter ended March 2024. There were no Sales reported in the quarter ended March 2025 and during the previous quarter ended March 2024. For the full year,net loss reported to Rs 0.12 crore in the year ended March 2025 as against net loss of Rs 0.09 crore during the previous year ended March 2024. There were no Sales reported in the year ended March 2025 and during the previous year ended March 2024.Powered by Capital Market - Live

Net profit of Laurus Labs rose 209.05% to Rs 233.67 crore in the quarter ended March 2025 as against Rs 75.61 crore during the previous quarter ended March 2024. Sales rose 19.49% to Rs 1720.30 crore in the quarter ended March 2025 as against Rs 1439.67 crore during the previous quarter ended March 2024. For the full year,net profit rose 123.18% to Rs 358.32 crore in the year ended March 2025 as against Rs 160.55 crore during the previous year ended March 2024. Sales rose 10.18% to Rs 5553.96 crore in the year ended March 2025 as against Rs 5040.83 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1720.301439.67 19 5553.965040.83 10 OPM %24.4516.77 -19.0015.42 - PBDT422.77209.52 102 914.38620.94 47 PBT312.34107.27 191 484.29236.36 105 NP233.6775.61 209 358.32160.55 123 Powered by Capital Market - Live

Net profit of Adani Energy Solutions rose 79.05% to Rs 647.15 crore in the quarter ended March 2025 as against Rs 361.44 crore during the previous quarter ended March 2024. Sales rose 35.43% to Rs 6374.58 crore in the quarter ended March 2025 as against Rs 4706.85 crore during the previous quarter ended March 2024. For the full year,net profit declined 6.80% to Rs 1059.97 crore in the year ended March 2025 as against Rs 1137.28 crore during the previous year ended March 2024. Sales rose 43.11% to Rs 23767.09 crore in the year ended March 2025 as against Rs 16607.36 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales6374.584706.85 35 23767.0916607.36 43 OPM %32.0033.26 -29.7334.39 - PBDT1435.601019.46 41 4486.843555.64 26 PBT973.95551.95 76 2580.891779.56 45 NP647.15361.44 79 1059.971137.28 -7 Powered by Capital Market - Live

Net profit of Sterling & Wilson Renewable Energy rose 3745.83% to Rs 55.38 crore in the quarter ended March 2025 as against Rs 1.44 crore during the previous quarter ended March 2024. Sales rose 113.84% to Rs 2519.11 crore in the quarter ended March 2025 as against Rs 1178.01 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 81.45 crore in the year ended March 2025 as against net loss of Rs 211.92 crore during the previous year ended March 2024. Sales rose 107.61% to Rs 6301.86 crore in the year ended March 2025 as against Rs 3035.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2519.111178.01 114 6301.863035.37 108 OPM %5.302.49 -3.92-0.74 - PBDT89.8538.20 135 176.88-155.67 LP PBT86.7233.74 157 162.54-172.32 LP NP55.381.44 3746 81.45-211.92 LP Powered by Capital Market - Live

On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. Reported EBITDA rose 9% year-on-year to Rs 363 crore in Q4 March 2025. EBITDA margin (%) stood at 35% in Q4FY25, lower than 35.7% in Q4FY24. For the full year, net profit declined 2.71% to Rs 496.20 crore while net sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 over the year ended March 2024. Reported EBITDA rose 1% year-on-year to Rs 1,114 crore in FY25. EBITDA margin (%) stood at 30% in FY25, lower than 30.9% in FY24. In its outlook for FY26, the Syngene management anticipates the reported revenue growth will likely be in the mid-single digits. They also foresee the EBITDA margin moderating from current levels to the mid-twenties and a year-on-year decline in profit after tax. Commenting on the results, Peter Bains, managing director and CEO, Syngene International, said, Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit. Deepak Jain, chief financial officer, Syngene International, said, Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax. The company's board recommended a final dividend of Re 1.25 per equity share for the financial year 2024-25. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Powered by Capital Market - Live

The Nifty May 2025 futures closed at 24,375, a premium of 128.3 points compared with the Nifty's closing of 24,246.70 in the cash market. In the cash market, the Nifty 50 declined 82.25 points or 0.34% to 24,246.70. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, jumped 1.81% to 16.25. Reliance Industries, HDFC Bank and IndusInd Bank were the top trading individual stock futures contracts in the F&O segment of the NSE. The May 2025 F&O contracts will expire on 29 May 2025.Powered by Capital Market - Live

TajGVK Hotels & Resorts announced that G Indira Krishna Reddy will retire as Managing Director from close of business hours on 24 April 2025. Powered by Capital Market - Live

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing. This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control. Powered by Capital Market - Live